Evotec (ETR:EVT) Trading Down 1.4% - What's Next?

Key Points

• Evotec SE's stock decreased by 1.4% during mid-day trading on Monday, with prices dropping to a low of €6.76 ($7.87) and closing at €6.95 ($8.08).
• Trading volume fell significantly, with approximately 663,097 shares changing hands, marking a 51% decline from the average daily volume of 1,360,000 shares.
• Evotec, which has a market capitalization of $1.25 billion, is involved in drug discovery and development across various therapeutic areas, including cancer, autoimmune diseases, and diabetes.

Evotec SE (ETR:EVT - Get Free Report)'s stock price dropped 1.4% during trading on Monday . The stock traded as low as €6.76 ($7.87) and last traded at €6.95 ($8.08). Approximately 663,097 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 1,360,000 shares. The stock had previously closed at €7.05 ($8.19).

Evotec Price Performance

The company's 50-day moving average price is €7.04 and its two-hundred day moving average price is €7.16. The company has a market capitalization of $1.24 billion, a P/E ratio of -7.23, a price-to-earnings-growth ratio of 0.98 and a beta of 1.05.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.